Compare Stocks → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLSNNASDAQ:FCSCNASDAQ:SEELNASDAQ:TLGT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsFCSCFibrocell Science$3.00$3.00$1.45▼$3.28$29.28M1.6778,673 shsN/ASEELSeelos Therapeutics$0.33$0.75$0.32▼$49.80$4.48M1.88427,947 shs383,013 shsTLGTTeligent$0.03$0.17▼$1.60N/AN/AN/A6,460 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSNImunon0.00%0.00%0.00%0.00%0.00%FCSCFibrocell Science0.00%0.00%0.00%0.00%0.00%SEELSeelos Therapeutics-2.63%-25.30%-35.72%-73.08%-98.41%TLGTTeligent0.00%0.00%0.00%0.00%0.00%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AN/AN/AN/AN/ASEELSeelos Therapeutics1.8955 of 5 stars3.24.00.00.00.60.00.0TLGTTeligentN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSNImunonN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/ASEELSeelos Therapeutics2.33Hold$70.0021,300.18% UpsideTLGTTeligentN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSNImunon$500K0.00N/AN/A$9.66 per share0.00FCSCFibrocell Science$350K83.66N/AN/A$0.98 per share3.06SEELSeelos Therapeutics$2.20M2.03N/AN/A($3.42) per share-0.10TLGTTeligentN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AFCSCFibrocell Science-$10.28M-$1.45N/AN/AN/AN/A23.10%10.56%N/ASEELSeelos Therapeutics-$37.88MN/A0.00∞N/A-1,719.56%N/A-517.23%5/20/2024 (Estimated)TLGTTeligentN/AN/A0.00N/AN/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSNImunonN/AN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AN/ASEELSeelos TherapeuticsN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSNImunon0.136.526.52FCSCFibrocell Science0.475.095.09SEELSeelos TherapeuticsN/A0.140.14TLGTTeligentN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSNImunon12.97%FCSCFibrocell Science36.72%SEELSeelos Therapeutics23.37%TLGTTeligentN/AInsider OwnershipCompanyInsider OwnershipCLSNImunon4.66%FCSCFibrocell Science1.10%SEELSeelos Therapeutics5.40%TLGTTeligent0.17%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLSNImunon277.10 million6.77 millionOptionableFCSCFibrocell Science199.76 millionN/AOptionableSEELSeelos Therapeutics1513.68 million12.94 millionOptionableTLGTTeligent2,357N/AN/AOptionableFCSC, SEEL, CLSN, and TLGT HeadlinesSourceHeadlineTopical pain reliever recalled for problem that can cause ‘severe morbidity, even death’charlotteobserver.com - June 7 at 10:18 AMβ1 Adrenoceptor Agonists Market 2023 Newest Industry Data ... - StreetBuzznews.google.com - May 13 at 1:32 AMLidocaine Ointment Market Upcoming Trends, Size, Key Players ... - Taiwan Newsnews.google.com - May 13 at 1:32 AMGlobal Mobile Value-Added Services (VAS) Industry Market Report ... - Industry Todaynews.google.com - May 11 at 4:41 AMGlobal Clindamycin Phosphate Topical Market Analysis, Share ... - The Northwestern Examinernews.google.com - May 8 at 10:54 AMDry Skin Treatment Market Products, Share, Types, Applications, Growth, Insights and Forecasts Report to 2028 - openPRnews.google.com - May 8 at 5:54 AMMobile Value-Added Services (VAS) Market Size, Growth ... - Digital Journalnews.google.com - May 8 at 5:54 AMMobile Value-Added Services (VAS) Market 2023 Global Insights ... - The Northwestern Examinernews.google.com - May 5 at 9:12 AMEpinephrine For Allergy Treatment Market Dynamic Growth Factors ... - Digital Journalnews.google.com - May 3 at 7:08 AMErythromycin Market with Focus on Growth Analysis, Production ... - Digital Journalnews.google.com - May 2 at 8:42 AMFrom 2023 to 2031 Mobile Value-Added Services (VAS) Market ... - Digital Journalnews.google.com - April 29 at 8:17 AMTremendous Growth Of Drugs To Relieve Paraneoplastic Pemphigus Market (2023-2030 )Industry Insights, SWOT Anal - openPRnews.google.com - April 28 at 10:17 PMDrugs to Relieve Paraneoplastic Pemphigus Market 2023 Provides Top Companies Data, Top Key Players, Types and - openPRnews.google.com - April 26 at 1:32 PMTopical Drug Delivery Market Production Capacity Estimates, Industry Size, Current Trend, Competition, Growth, - openPRnews.google.com - April 26 at 8:32 AMTriamcinolone Market | Driving Factors, Industry Analysis ... - Taiwan Newsnews.google.com - April 24 at 4:23 PMIDT Corp. Cl Bwsj.com - April 23 at 2:59 AMMobile Value-Added Services (VAS) Markets edge up Strategic ... - Digital Journalnews.google.com - April 17 at 2:17 PMHikma Names Injectables Chief Mishlawi As CEO - Generics Bulletinnews.google.com - April 12 at 1:13 PMMobile Value-Added Services (VAS) Market is Anticipated to Shown ... - Digital Journalnews.google.com - April 10 at 1:16 PMEverstream Names Ken Fitzpatrick as President and Chief Executive ... - Joplin Globenews.google.com - April 6 at 1:58 PMLidocaine Ointment Market Growth Till, 2023-2030: Coherent Market ... - Digital Journalnews.google.com - March 29 at 7:08 AMMobile Value-Added Services (VAS) Maket Is Set to Fly High in ... - Digital Journalnews.google.com - March 29 at 2:07 AMGonorrhea Treatment Market Size 2023 - Current Sales Analysis, Upcoming Trends, Opportunities, Development His - openPRnews.google.com - March 28 at 10:26 AMBankruptcy Standing: An Introduction to a Multitude | Reed Smith ... - JD Supranews.google.com - March 25 at 8:59 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Fibrocell ScienceNASDAQ:FCSCFibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.Seelos TherapeuticsNASDAQ:SEELSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.TeligentNASDAQ:TLGTTeligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.